首页> 美国卫生研究院文献>Frontiers in Pharmacology >Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
【2h】

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma

机译:C-MYC,BCL-2和BCL-6蛋白表达与基因易位性作为生物标志物在弥漫性大B细胞淋巴瘤诊断和预后中的相关性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study investigates the protein expression of C-MYC, BCL-2, and BCL-6 in diffuse large B-cell lymphoma (DLBCL) and their relationship with genetic abnormalities. A retrospective study of 42 cases on paraffin-embedded tissue specimens diagnosed with DLBCL was performed using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The expression of C-MYC, BCL-2, BCL-6 protein, and gene abnormalities in these tissue samples was analyzed. The relationship in genetic abnormalities and Ki-67, Hans classification, gender, and age was also evaluated. It was found that the positive rate of C-MYC expression was 47.6% (20/42), the rate of C-MYC gene abnormality was 26.2% (11/42), in which gene translocation accounted for 23.8% (10/42) and gene amplification 2.4% (1/42); C-MYC protein expression was positively correlated with C-MYC gene translocation (χ2 = 11.813; P = 0.001); C-MYC gene translocation was mainly found in germinal center B cell type (χ2 = 4.029; P = 0.045). The positive rate of BCL-2 protein expression was 85.71% (36/42), the positive rate of translocation was 42.86% (18/42) and the amplification rate was 26.19% (11/42); the overexpression of BCL-2 protein was correlated with the BCL-2 translocation (χ2 = 3.407; P = 0.029). The positive rate of BCL-6 protein expression was 45.24% (19/42), the positive rate of BCL-6 translocation was 14.29% (6/42) and the positive rate of BCL-6 amplification was 7.14% (3/42); the overexpression of BCL-6 protein was significantly correlated with BCL-6 translocation (χ2 = 6.091; P = 0.014). The Ki-67 index was significantly higher in C-MYC translocation cases than in non-C-MYC translocation cases (χ2 = 4.492; P = 0.034). Taken together, our results suggest that the protein expression of C-MYC, BCL-2, and BCL-6 are positively correlated with their gene translocation. Overexpression of C-MYC, BCL-2, BCL-6 protein suggests the possibility of translocation. Therefore, immunohistochemical detection of C-MYC, BCL-2, and BCL-6 are useful in diagnosis and prognosis of DLBCL.
机译:本研究调查了C-MYC,BCL-2和BCL-6在弥漫性大B细胞淋巴瘤(DLBCL)中的蛋白表达及其与遗传异常的关系。使用免疫组织化学(IHC)和荧光原位杂交(FISH)对42例诊断为DLBCL的石蜡包埋组织标本进行回顾性研究。分析了这些组织样品中C-MYC,BCL-2,BCL-6蛋白的表达以及基因异常。还评估了遗传异常与Ki-67,汉斯分类,性别和年龄之间的关系。发现C-MYC表达阳性率为47.6%(20/42),C-MYC基因异常率为26.2%(11/42),其中基因易位占23.8%(10/42)。 )和基因扩增2.4%(1/42); C-MYC蛋白表达与C-MYC基因易位呈正相关(χ 2 = 11.813; P = 0.001)。 C-MYC基因易位主要存在于生发中心B细胞类型中(χ 2 = 4.029; P = 0.045)。 BCL-2蛋白表达阳性率为85.71%(36/42),易位阳性率为42.86%(18/42),扩增率为26.19%(11/42); BCL-2蛋白的过度表达与BCL-2易位有关(χ 2 = 3.407; P = 0.029)。 BCL-6蛋白表达的阳性率为45.24%(19/42),BCL-6移位的阳性率为14.29%(6/42),BCL-6扩增的阳性率为7.14%(3/42) ); BCL-6蛋白的过表达与BCL-6易位显着相关(χ 2 = 6.091; P = 0.014)。在C-MYC易位病例中,Ki-67指数显着高于非C-MYC易位病例(χ2= 4.492; P = 0.034)。综上所述,我们的结果表明C-MYC,BCL-2和BCL-6的蛋白质表达与其基因易位呈正相关。 C-MYC,BCL-2,BCL-6蛋白过表达提示易位。因此,C-MYC,BCL-2和BCL-6的免疫组织化学检测可用于DLBCL的诊断和预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号